Simulations Plus Outlines Paths to Win at 2023 Investor Day
November 14 2023 - 8:00AM
Business Wire
Demonstrates How Putting Clients First
Drives Growth and Fuels Innovation
Reiterates 2024 Guidance
Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a
leading provider of modeling and simulation software and services
for pharmaceutical safety and efficacy, today will host its
investor day virtually, as previously announced.
Chief Executive Officer Shawn O’Connor, Chief Financial Officer
Will Frederick, and other members of the leadership team will
present an in-depth review of the Company’s client-centric business
model as well as outline how its new organizational structure
better aligns its business with their clients and facilitates
future growth. During the event, there will be an opportunity for
attendees to ask questions during the Q&A session.
"We look forward to sharing a comprehensive update of our
strategic objectives and how putting our clients first drives
growth and fuels innovation,” said O’Connor.
“Our paths to win are centered on four key areas: providing
unparalleled offerings and a client-centric business model to our
clients, continuing to focus on areas that clients find most
important, leading the industry in ease-of-use, and building upon
our strong relationship-based model.
“Our reorganization reflects the spirit of collaboration that is
taking place throughout our organization. Our objective is to
operate as ‘one company’ and advance our internal alignment with
our clients’ needs as we transition our company from
acquisition-based divisions to strategic business units defined by
our areas of scientific expertise.
“We have a long history of innovation in biosimulation that is
transforming drug development and R&D and a strong financial
position to fund our growth. Today, our highly experienced
leadership team will demonstrate the rich future for growth
opportunities here at Simulations Plus.”
Reiterates Fiscal 2024 Guidance
The Company reiterated previously announced fiscal 2024 guidance
which is based upon a status quo outlook compared to fiscal
2023.
- Revenues are expected to increase in the range of 10-15%, or
$66 to $69 million.
- Software expected to contribute 55-60% of revenues and Services
expected to contribute 40-45%, reflecting the increased Services
revenue from the Immunetrics acquisition.
- Diluted earnings per share is expected to be in the range $0.66
to $0.68, or an annual increase of 35-39%.
The live webcast will begin at 1:00 p.m. Eastern time and
conclude at approximately 3:00 p.m. ET. The webcast and
presentations can be accessed on the Investor Relations section of
the company’s website at
https://www.simulations-plus.com/investorscorporate-profile/conference-calls/.
Interested parties unable to attend will be able to view and listen
to an archived copy of the webcast following the conclusion of the
event.
About Simulations Plus, Inc.
Serving clients worldwide for more than 25 years, Simulations
Plus is a leading provider in the biosimulation market providing
software and consulting services supporting drug discovery,
development, research, and regulatory submissions. We offer
solutions that bridge artificial intelligence (AI)/machine
learning, physiologically based pharmacokinetics, quantitative
systems pharmacology/toxicology, and population PK/PD modeling
approaches. Our technology is licensed and applied by major
pharmaceutical, biotechnology, and regulatory agencies worldwide.
For more information, visit our website at
www.simulations-plus.com. Follow us on LinkedIn | Twitter |
YouTube.
Environmental, Social, and Governance (ESG)
We focus our Environmental, Social, and Governance (ESG) efforts
where we can have the most positive impact. To learn more about our
latest initiatives and priorities, please visit our website to read
our 2022 ESG update.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231114820961/en/
Simulations Plus Investor Relations
Renee Bouche 661-723-7723 renee.bouche@simulations-plus.com
Financial Profiles Tamara Gonzalez
310-622-8234 slp@finprofiles.com
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Sep 2024 to Oct 2024
Simulations Plus (NASDAQ:SLP)
Historical Stock Chart
From Oct 2023 to Oct 2024